ДИНАМИКА ХИМЕРИЗМА КАК ФАКТОР ПРОГНОЗА РАЗВИТИЯ РЕЦИДИВОВ ПОСЛЕ АЛЛОГЕННОЙ ТРАНСПЛАНТАЦИИ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК ПРИ ОНКОГЕМАТОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЯХ

Рецидив основного заболевания остается одной из главных проблем и наиболее частых причин смертности после аллогенной трансплантации гемопоэтических стволовых клеток (аллоТГСК) у пациентов с онкогематологическими заболеваниями (ОГЗ). Мониторинг химеризма позволяет оценить приживление трансплантата и предсказать развитие рецидивов. Изучены результаты 104 аллоТГСК, которые были проведены с 2009 по 2016 г. у пациентов с ОГЗ. Установлено, что увеличивающийся смешанный химеризм (СХ) является неблагоприятным фактором прогноза для бес- событийной выживаемости (HR = 6,9, p < 0,0001) и ассоциирован с высоким риском развития рецидивов (HR = 12,2, p < 0,0001) после аллоТГСК. Бессобытийная выживаемость в группе с полным донорским (ПДХ), уменьшающимся СХ и увеличивающимся СХ составила 68,1 ± 6,4; 60,0 ± 21,9 и 0 % (p < 0,0001), кумулятивная частота развития рецидивов – 10,8 ± 4,6; 0 и 81,3 ± 10,8 % (p < 0,0001) соответственно. Увеличение клеток реципиента выявлялось за 2–435 (медиана 23,5) сут до гематологического рецидива в 10 (62,5%) из 16 случаев. Увеличивавшийся СХ раньше и чаще выявлялся в костном мозге, чем в периферической крови (p = 0,06). В разгар гематологического рецидива химеризм в периферической крови может быть полностью донорским. У пациентов с полным донорским химеризмом развитие острой реакции «трансплантат против хозяина» наблюдалось чаще, чем у пациентов с СХ (p = 0,0004). 

1. Barrett, A. J. Relapse after allogeneic stem cell transplantation / A. J. Barrett, M. Battiwalla // Expert Rev. of Hematol. – 2010. – Vol. 3, iss. 4. – P. 429–441. doi: 10.1586/ehm.10.32.

2. D’Souza, A. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2016 [Electronic resourse] / A. D’Souza, X. Zhu // CIBMTR. – Mode of access: http://www.cibmtr.org. – Date of access: 05.04.2017.

3. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation / D. L. Porter [et al.] // Biology of Blood and Marrow Transplantation. – 2010. – Vol. 16, iss. 11. – P. 1467–1503. – Doi: 10.1016/j.bbmt.2010.08.001.

4. LaBelle, J. L. Stem cell transplant as an immunomodulatory tool for children with hematologic malignancies / J. L. LaBelle, J. M. Cunningham // American Society of Clinical Oncology Educational Book. – 2013. – P. 347–352. – Doi: 10.1200/EdBook_AM.2013.33.e347.

5. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation / G. Thanarajasingam [et al.] // Biology of Blood and Marrow Transplantation. – 2013. – Vol. 19, iss. 12. – P. 1713–1718. – Doi: 10.1016/j.bbmt.2013.09.011.

6. Extramedullary relapse of acute leukemia after allogeneichematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblasticleukemia / L. Ge [et al.] // Biology of Blood and Marrow Transplantation. – 2014. – Vol. 20, iss. 7. – P. 1040–1047. – Doi: 10.1016/j.bbmt.2014.03.030.

7. Management of relapse after allo-SCT for AML and the role of second transplantation / B. N. Savani [et al.] // Bone Marrow Transplantation. – 2009. – Vol. 44, iss. 12. – P. 769–777. – Doi: 10.1038/bmt.2009.300.

8. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation / M. Mielcarek [et al.] // Biology of Blood and Marrow Transplantation. – 2007. – Vol. 13, iss. 10. – P. 1160–1168. – Doi: 10.1016/j.bbmt.2007.06.007.

9. Kröger, N. Minimal residual disease following allogeneic hematopoietic stem cell transplantation / N. Kröger, K. Miyamura, M. R. Bishop // Biology of Blood and Marrow Transplantation. – 2011. – Vol. 20, iss. 1. – P. S94–S100. – Doi: 10.1016/j.bbmt.2010.10.031.

10. POGO MRD Working Group. Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group / U. H. Athale [et al.] // Pediatric Blood & Cancer. – 2016. – Vol. 63, iss. 6. – P. 973–982. – Doi: 10.1002/pbc.25939.

11. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia / U. Bacher [et al.] // Sci. World J. – 2011. – Vol. 11. – P. 310–319. – Doi: 10.1100/tsw.2011.16.

12. Establishment of complete and mixed donor chimerism afterallogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings of the International bone marrow transplant registry and the american society of blood and marrow transplantation / J. H. Antin [et al.] // Biology of Blood and Marrow Transplantation. – 2001. – Vol. 7, iss. 9. – P. 473–485. – Doi: 10.1053/bbmt.2001.v7.pm11669214.

13. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia / T. H. Terwey [et al.] // Biology of Blood and Marrow Transplantation. – 2014. – Vol. 20, iss. 10. – P. 1522–1529. – Doi: 10.1016/j.bbmt.2014.05.026.

14. How and when should we monitor chimerism after allogeneic stem cell transplantation? / P. Bader [et al.] // Bone Marrow Transplantation. – 2005. – Vol. 35, iss. 2. – P. 107–119. – Doi: 10.1038/sj.bmt.1704715.

15. Increasing mixed chimerism defines a high-risk group of childhoodacute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective / P. Bader [et al.] // Bone Marrow Transplantation. – 2004. – Vol. 33, iss. 8. – P. 815–821. – Doi: 10.1038/sj.bmt.1704444.

16. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? / P. Bader [et al.] // J. of Clin. Oncol. – 2004. – Vol. 22, iss. 9. – P. 1696–1705. – Doi: 10.1200/JCO.2004.05.198.

17. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation / E. Rettinger [et al.] // Blood. – 2011. – Vol. 118, iss. 20. – P. 5681–5688. – Doi: 10.1182/blood-2011-04-348805.

18. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation / R. Zeiser [et al.] // Leukemia. – 2005. – Vol. 19, iss. 5. – P. 814–821. – Doi: 10.1038/sj.leu.2403719.

19. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences / M. Koldehoff [et al.] // Am. J. of Hematol. – 2006. – Vol. 81, iss. 10. – P. 735–746. – Doi: 10.1002/ajh.20693.

20. Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome / E. Elkaim [et al.] // Br. J. of Haematol. – 2014. – Vol. 166, iss. 4. – P. 557–565. – Doi: 10.1111/bjh.12918.

21. Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant / E. Nikolousis [et al.] // Leukemia Res. – 2013. – Vol. 37, iss. 5. – P. 561–565. – Doi: 10.1016/j.leukres.2013.01.010.

22. Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse / J. E. van Leeuwen [et al.] // Blood. – 1993. – Vol. 82, iss. 6. – P. 1921–1928.

23. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction / M. Alizadeh [et al.] // Blood. – 2002. – Vol. 99, iss. 12. – P. 4618–4625.

24. Количественный анализ химеризма после аллогенной трансплантации гемопоэтических стволовых клеток молекулярно-генетическими методами / В. А. Лавриненко [и др.] // Онкогематология = Oncohematology. – 2014. – № 2. – С. 29–36.

25. Kaplan, E. Nonparametric estimation from incomplete observations / E. Kaplan, P. Meier // J. of the Am. Statistical Association. – 1958. – Vol. 53, iss. 282. – P. 457–481.

26. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators / T. A. Gooley [et al.] // Statistics in Medicine. – 1999. – Vol. 18, iss. 6. – P. 695–706.

27. Gray, R. A class of K-sample tests for comparing the cumulative incidence of a competing rick / R. Gray // The Annals of Statistics. – 1988. – Vol. 16, iss. 3. – P. 1140–1154.

28. Nagoya Blood and Marrow Transplantation Group. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalandose and is predictive of relapse / N. Imahashi [et al.] // Annals of Hematol. – 2015. – Vol. 94, iss. 7. – P. 1139–1148. – Doi: 10.1007/s00277-015-2312-4.

29. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen / B. Saito [et al.] // Biology of Blood and Marrow Transplantation. – 2008. – Vol. 14, iss. 10. – P. 1148–1155. – Doi: 10.1016/j.bbmt.2008.07.013.

30. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival / J. Koreth [et al.] // Biology of Blood and Marrow Transplantation. – 2014. – Vol. 20, iss. 10. – P. 1516–1521. – Doi: 10.1016/j.bbmt.2014.05.025.

31. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults / P. Peterlin [et al.] // Biology of Blood and Marrow Transplantation. – 2015. – Vol. 21, iss. 1. – P. 180–184. – Doi: 10.1016/j.bbmt.2014.08.018.

32. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia / C. Huisman [et al.] // Bone Marrow Transplantation. – 2007. – Vol. 39, iss. 5. – P. 285–291. – Doi: 10.1038/sj.bmt.1705582.

33. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia / B. Wiedemann [et al.] // Experim. Hematol. – 2010. – Vol. 38, iss. 12. – P. 1261–1271. – Doi: 10.1016/j.exphem.2010.08.006.

34. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-timePCR of null alleles and insertion/deletion polymorphisms / A. Jiménez-Velasco [et al.] // Leukemia. – 2005. – Vol. 19, iss. 3. – P. 336–343. – Doi: 10.1038/sj.leu.2403622.

35. Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse / O. Horky [et al.] // Inter. J. of Lab. Hematol. – 2011. – Vol. 33, iss. 1. – P. 57–66. – Doi: 10.1111/j.1751-553X.2010.01249.x.

36. Monitoring of hematopoietic chimerism after transplantation for pediatric myelodysplastic syndrome: real-time or conventional short tandem repeat PCR in peripheral blood or bone marrow? / A. M. Willasch [et al.] // Biology of Blood and Marrow Transplantation. – 2014. – Vol. 20, iss. 12. – P. 1918–1925. – Doi: 10.1016/j.bbmt.2014.07.030.

37. Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT / X. Y. Qin [et al.] // Bone Marrow Transplantation. – 2014. – Vol. 49, iss. 10. – P. 1269–1277. – Doi: 10.1038/bmt.2014.158.

38. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia / M. Barrios [et al.] // Haematologica. – 2003. – Vol. 88, iss. 7. – P. 801–810.

39. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes / X. D. Mo [et al.] // Biology of Blood and Marrow Transplantation. – 2014. – Vol. 20, iss. 12. – P. 2023–2028. – Doi: 10.1016/j.bbmt.2014.08.023.

40. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation / J. Mattsson [et al.] // Leukemia. – 2001. – Vol. 15, iss. 12. – P. 1976–1985.